quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:15:00·14h
PRRelease
Longeveron Inc. logo
Eli Lilly and Company logo
Novo Nordisk A/S logo
+1

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

LGVN· Longeveron Inc.LLY· Eli Lilly and CompanyNVO· Novo Nordisk A/SVKTX· Viking Therapeutics Inc.
Health Care
Original source

Companies

  • LGVN
    Longeveron Inc.
    Health Care
  • LLY
    Eli Lilly and Company
    Health Care
  • NVO
    Novo Nordisk A/S
    Health Care
  • VKTX
    Viking Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 26VKTXUpdateWolfe Research-
  • Mar 26NVOUpdateWolfe Research-
  • Mar 18NVOUpdateBernstein-
  • Mar 18NVOUpdateBernstein$175.00
  • Mar 17LLYUpdateHSBC Securities$850.00
  • Mar 10NVOUpdateTD Cowen$42.00

Related

  • PR1d
    Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
  • INSIDER2d
    SEC Form 4 filed by Sulzberger Gabrielle
  • INSIDER2d
    SEC Form 4 filed by Luciano Juan R
  • INSIDER2d
    SEC Form 4 filed by Fyrwald J Erik
  • INSIDER2d
    SEC Form 4 filed by Alvarez Ralph
  • SEC3d
    SEC Form 6-K filed by Novo Nordisk A/S
  • PR3d
    Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
  • SEC3d
    SEC Form 6-K filed by Novo Nordisk A/S
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022